0505 Empowering OSA Care: Patient Profiles and Treatment Patterns in Japan

Abstract Introduction In Japan, the estimated prevalence of OSA is around 15%, and about 20% of adult males and 10% of postmenopausal women are estimated to have moderate-to-severe OSA. Despite the high prevalence, few studies have assessed the patient journey from sleep test to diagnosis and treatment initiation. This study aims to assess the patient journey and the associated real world treatment pathways. Methods This study utilized the retrospective longitudinal real-world Japan Claims database, standardized to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) from January 1, 2017, to May 31, 2022. The data encompassed patient demographics, OSA diagnoses, sleep study records, and treatment details. Adults over 18 with a minimum of 6 months of enrollment pre-diagnosis or treatment initiation were included. Results Of the 17,631 adults with OSA, 70.5% were aged 40-59, and 83.6% were male. Overnight polysomnography was used to diagnose 91% of the cases. All patients had at least one BMI reported within 1 year of OSA diagnosis with 9,185 adults (52.1%) having BMI =25.0 kg/m². Dyslipidemia and hypertension were present in 19.2% and 18.5% of patients, respectively. The mean time from the first sleep study to OSA diagnosis was 7 months (SD: 16.8). 9,522 patients received OSA treatment, with 75% aged between 40-59 years and a male predominance of 92.8%. Mean time from OSA diagnosis to treatment was 3.5 months (SD: 5.1). Majority (98.6%) received Positive Airway Pressure (PAP) therapy as the primary treatment. Bariatric and upper airway surgeries were less common. PAP adherence within the first year after treatment initiation was higher amongst patients with obesity (93.1%) compared to those without (82.7%), with mean time on therapy being approximately 11.8 months (SD:0.2). Conclusion Our study highlights a significant prevalence of OSA, especially among middle-aged males and individuals with higher BMI. PAP therapy emerges as the primary OSA treatment with consistent adherence within the first year of treatment. Further research is needed to better understand the treatment outcomes and the unmet needs with the current standard of care for people living with OSA and Obesity. Support (if any)